In ClinicalTrials.gov, there is a Phase 1 study investigating the safety and efficacy of HER2 chimeric antigen receptor specific cytotoxic T lymphocytes (HER2 specific CAR T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system including HER2 specific CAR T cell react to the tumor (Clinical NCT number: NCT03740256). Here, ERBB2 is linked to neoplasm.